Oct 9, 2025 12:12PM Canaccord Genuity Downgrades Akero Therapeutics (AKRO) to Hold

Oct 9, 2025 12:12PM LifeSci Capital Downgrades Akero Therapeutics (AKRO) to Market Perform

Oct 9, 2025 06:02AM Novo Nordisk to acquire Akero Therapeutics for up to $5.2 billion

Oct 7, 2025 07:00AM Akero to present efruxifermin data at liver disease conference

Sep 4, 2025 06:13AM H.C. Wainwright Starts Akero Therapeutics (AKRO) at Buy

Aug 8, 2025 09:38AM Akero Therapeutics (AKRO) Tops Q2 EPS by 4c

Aug 6, 2025 10:07AM Morgan Stanley Reiterates Overweight Rating on Akero Therapeutics (AKRO) (premarket)

Aug 4, 2025 05:30AM TD Cowen Starts Akero Therapeutics (AKRO) at Buy

Jun 13, 2025 11:43AM Jefferies: 'We highlight multiple de-risked or commercial-stage names that we think have promising M&A potential'

May 20, 2025 01:10PM Akero Therapeutics (AKRO) explores potential sale after interest - source

May 13, 2025 02:26PM Jefferies Reiterates Buy Rating on Akero Therapeutics (AKRO)

May 13, 2025 06:25AM Akero Therapeutics (AKRO) Tops Q1 EPS by 11c

May 13, 2025 04:52AM Akero Therapeutics (AKRO) PT Lowered to $78 at Citi

May 12, 2025 02:38PM Akero Therapeutics (AKRO) PT Lowered to $84 at Morgan Stanley

May 9, 2025 07:15AM Akero Therapeutics (AKRO) Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of Medicine

May 9, 2025 06:41AM Akero Therapeutics (AKRO) Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin

Apr 30, 2025 12:41AM Clear Street Starts Akero Therapeutics (AKRO) at Buy

Apr 2, 2025 07:04AM Smid cap biotech investors must stop chasing binary events says Cantor Fitzgerald

Mar 3, 2025 06:15AM Akero Therapeutics (AKRO) PT Raised to $75 at H.C. Wainwright

Jan 29, 2025 04:08PM Akero Therapeutics (AKRO) PT Raised to $75 at Jefferies

Jan 28, 2025 06:35AM Akero Therapeutics (AKRO) PT Raised to $73 at Canaccord Genuity

Jan 28, 2025 05:02AM Akero Therapeutics (AKRO) PT Raised to $80 at Citi

Jan 27, 2025 04:01PM Akero Therapeutics (AKRO) Announces Proposed Public Offering of Common Stock

Jan 27, 2025 02:38PM Akero Therapeutics (AKRO) call put ratio 1 call to 3.2 puts as share price up 91%

Jan 27, 2025 11:47AM Akero Therapeutics (AKRO) PT Raised to $72 at H.C. Wainwright

Jan 27, 2025 10:36AM Akero Therapeutics (AKRO) PT Raised to $96 at Morgan Stanley

Jan 27, 2025 10:30AM Jefferies Reiterates Buy Rating on Akero Therapeutics (AKRO)

Jan 27, 2025 06:32AM Akero Therapeutics (AKRO) Reports Prelim Topline Results Showing Statistically Significant Reversal in Phase 2b SYMMETRY Study

Jan 24, 2025 04:08PM Akero Therapeutics (AKRO) to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH

Jan 17, 2025 06:39AM H.C. Wainwright Reiterates Buy Rating on Akero Therapeutics (AKRO)

Jan 16, 2025 02:56PM Akero Therapeutics (AKRO) 2275 contracts of March 27.50 calls trade

Jan 9, 2025 05:18PM Notice to Akero Therapeutics, Inc. (AKRO) Shareholders: Grabar Law Office Is Investigating Claims on Your Behalf

Dec 30, 2024 05:30PM Kuehn Law Encourages Investors of Akero Therapeutics, Inc. to Contact Law Firm

Dec 30, 2024 08:49AM Attention Long-Term Akero Therapeutics, Inc. (AKRO) Shareholders: Grabar Law Office Is Investigating Claims on Your Behalf

Dec 19, 2024 02:00PM 4 themes and 4 key biotech stocks for 2025: Jefferies

Nov 18, 2024 04:12AM Citi Starts Akero Therapeutics (AKRO) at Buy

Nov 15, 2024 11:01AM Akero Therapeutics (AKRO) to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD

Oct 20, 2024 10:00AM 4 biotech stocks to own to benefit from key Q4 catalysts

Sep 17, 2024 06:50AM H.C. Wainwright Reiterates Buy Rating on Akero Therapeutics (AKRO)

Aug 9, 2024 08:29AM Akero Therapeutics (AKRO) Tops Q2 EPS by 2c

Jun 12, 2024 07:44AM Canaccord Genuity Reiterates Buy Rating on Akero Therapeutics (AKRO)

Jun 11, 2024 05:02AM Wolfe Research Starts Akero Therapeutics (AKRO) at Outperform